Is Now Still a Good Time to Buy Gilead Sciences (GILD) Stock? Oppenheimer Says ‘Yes’

TipRanks2020-06-16

After Gilead Sciences' (GILD) antiviral drug remdesivir was identified as a potential treatment for COVID-19 earlier in the year, investors sent the stock up by 30%. But sentiment has somewhat soured ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

逸禅
2020-06-17
逸禅
说明中国的试验确实存在样本污染问题。

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2043332621?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2020-06-16 03:25","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2043332621","market":"us","top_or_hot":-1,"title":"Is Now Still a Good Time to Buy Gilead Sciences (GILD) Stock? Oppenheimer Says ‘Yes’","media":"TipRanks","content":"<div>\n<p>After Gilead Sciences' (GILD) antiviral drug remdesivir was identified as a potential treatment for COVID-19 earlier in the year, investors sent the stock up by 30%. But sentiment has somewhat soured ...</p>\n\n<a href=\"https://finance.yahoo.com/news/now-still-good-time-buy-192516593.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now Still a Good Time to Buy Gilead Sciences (GILD) Stock? Oppenheimer Says ‘Yes’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now Still a Good Time to Buy Gilead Sciences (GILD) Stock? Oppenheimer Says ‘Yes’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-06-16 03:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/now-still-good-time-buy-192516593.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After Gilead Sciences' (GILD) antiviral drug remdesivir was identified as a potential treatment for COVID-19 earlier in the year, investors sent the stock up by 30%. But sentiment has somewhat soured ...</p>\n\n<a href=\"https://finance.yahoo.com/news/now-still-good-time-buy-192516593.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://finance.yahoo.com/news/now-still-good-time-buy-192516593.html","article_id":"2043332621","we_media_id":null,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/now-still-good-time-buy-192516593.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2043332621","pubTimestamp":1592249116,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"After Gilead Sciences' (GILD) antiviral drug remdesivir was identified as a potential treatment for ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学","DIOD":"Diodes Incorporated"},"translate_title":"现在还是买入吉利德科学股票的好时机吗？ 奥本海默说“是”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1,"DIOD":0.9},"content_text":"After Gilead Sciences' (GILD) antiviral drug remdesivir was identified as a potential treatment for COVID-19 earlier in the year, investors sent the stock up by 30%. But sentiment has somewhat soured recently, with shares on a downtrend since the late April yearly peak.However, Oppenheimer analyst Hartaj Singh has no such concerns over Gilead’s long-term prospects, and tells investors, “We view any GILD weakness as a potential buying opportunity.”Singh identifies 3 possible reasons for the recent weakness. The first concerns a broader trend, as COVID-19’s impact has diminished, investors have shifted focus from the biotech sector to other industries. Secondly, Gilead has a “a tricky 2Q20 earnings report coming up,” one in which the full effect of the COVID-19 pandemic will be revealed.Lastly, the commercial opportunity for remdesivir has been questioned recently, as Wall Street has wondered about Gilead’s business model for the drug. Additionally, the drug’s development has also been a drain on resources which could be a factor heading into the quarterly statement. “Remdesivir investments might not be adequately reflected in 2Q/20 consensus leading to volatility into 2Q20 earnings,” said Singh.But what the skeptics appear to be missing by fixating solely on remdesivir, Singh says, is the pharma giant’s increasingly strong and diverse pipeline.The 5-star analyst said, “While sales/ earnings growth has started (per our upgrade thesis 01/19), we still see the Street ascribing little value to an emerging/quality pipeline. Launches for filgotinib in rheumatoid arthritis (2H20), ulcerative colitis (2021), magrolimab ('22) should buttress earlier stage data for HIV capsid (1H21), oral PD-1 (2020), nebulized remdesivir (2H20), etc,”Accordingly, Singh has an Outperform rating on GILD to go a with a $90 price target, which implies about 22% upside from current levels (To watch Singh’s track record, click here)The rest of Street has mixed views when considering Gilead’s prospects. Gilead's Hold consensus rating is based on 10 Buys, 14 Holds and 4 Sells. However, the bulls have the edge, as the average price target is $79.95 and implies possible upside of 9%. (See GILD stock analysis on TipRanks)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":955158854,"gmtCreate":1592335350778,"gmtModify":1704198922503,"author":{"id":"8529261215475","authorId":"8529261215475","name":"逸禅","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"说明中国的试验确实存在样本污染问题。","listText":"说明中国的试验确实存在样本污染问题。","text":"说明中国的试验确实存在样本污染问题。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/955158854","repostId":2043332621,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2043332621"}